ESC 2024

De-escalation of DAPT to ticagrelor monotherapy after coronary stenting does not increase ischemic risk and lowers major bleeding risk versus standard care.

Drug-coated balloon angioplasty with rescue stenting is inferior to drug-eluting stent implantation for adults with de novo coronary artery disease.

All-cause mortality and postoperative complications at 28 days after noncardiac surgery are similar for patients who continue or stop taking RAS inhibitors before surgery.

Asundexian 50 mg/day is associated with a higher incidence of stroke or systemic embolism than apixaban in high-risk patients with atrial fibrillation.

Finerenone treatment reduces the risk for CV death and heart failure in people with HF and mildly reduced or preserved ejection fraction, shows the FINEARTS-HF trial.

Vutrisiran reduces all-cause mortality and recurrent cardiovascular events in patients with transthyretin amyloid cardiomyopathy.

Research on vascular Ehlers-Danlos syndrome provides greater insight into the clinical and genetic characteristics of children with this condition.

A new risk prediction model incorporating the Clinical Frailty Scale and estimated plasma volume status allows reliable prediction of mortality in people with heart failure with preserved ejection fraction.

The clinical effect of evolocumab may be more pronounced in obese patients than in healthy weight patients.

A single pill containing a combination of perindopril, indapamide, amlodipine and bisoprolol was effective at managing blood pressure in patients with resistant hypertension.

Elevated HbA1c was seen in more than 35% of patients treated for acute coronary syndrome with percutaneous coronary intervention who were not previously diagnosed with diabetes. 

Patient outcomes at 1 year were improved with optical coherence tomography vs angiography in PCI for complex coronary lesions.